Skip to main content
. Author manuscript; available in PMC: 2022 Sep 1.
Published in final edited form as: Transplant Cell Ther. 2021 Jun 7;27(9):795.e1–795.e8. doi: 10.1016/j.jtct.2021.05.029

Figure 1:

Figure 1:

Cumulative incidence of CNS symptoms after allogeneic HCT

Abbreviations: Donor negative, recipient positive (D−/R+), donor positive, recipient negative (D+/R−), inherited chromosomally integrated HHV-6 (iciHHV-6)

Cumulative incidence probability estimates of time to first CNS symptom within the first 100 days after allogeneic HCT. Death was treated as a competing risk event. A: Cumulative incidence of CNS symptoms in iciHHV-6pos vs. iciHHV-6neg HCT recipients 1B: Cumulative incidence of CNS symptoms in iciHHV-6pos cases, stratified by HHV-6 species (HHV-6A vs. HHV-6B). C: Cumulative incidence of CNS symptoms in iciHHV6pos cases, stratified by donor/recipient status (D+/R− vs. R+).